| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Migraine Disorders | 129 | 2024 | 1701 | 16.880 |
Why?
|
| Migraine with Aura | 26 | 2022 | 204 | 5.130 |
Why?
|
| Stroke | 84 | 2023 | 9757 | 4.100 |
Why?
|
| Migraine without Aura | 15 | 2021 | 82 | 3.660 |
Why?
|
| Headache | 17 | 2022 | 1256 | 3.110 |
Why?
|
| Restless Legs Syndrome | 10 | 2019 | 233 | 2.940 |
Why?
|
| Cardiovascular Diseases | 57 | 2024 | 15500 | 2.810 |
Why?
|
| Brain Ischemia | 31 | 2021 | 3049 | 2.530 |
Why?
|
| Intracranial Hemorrhages | 10 | 2020 | 822 | 1.930 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 14 | 2016 | 2273 | 1.760 |
Why?
|
| Cholinesterase Inhibitors | 4 | 2024 | 242 | 1.690 |
Why?
|
| Aspirin | 24 | 2013 | 3133 | 1.650 |
Why?
|
| Headache Disorders | 5 | 2023 | 152 | 1.640 |
Why?
|
| Propensity Score | 11 | 2024 | 1913 | 1.600 |
Why?
|
| Risk Factors | 138 | 2024 | 74206 | 1.440 |
Why?
|
| Women's Health | 14 | 2023 | 2065 | 1.240 |
Why?
|
| Germany | 29 | 2024 | 875 | 1.230 |
Why?
|
| Humans | 380 | 2024 | 761504 | 1.180 |
Why?
|
| Cohort Studies | 84 | 2024 | 41487 | 1.120 |
Why?
|
| Tryptamines | 7 | 2022 | 93 | 1.110 |
Why?
|
| Tension-Type Headache | 3 | 2020 | 76 | 1.090 |
Why?
|
| France | 12 | 2019 | 497 | 1.030 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 4 | 2010 | 276 | 0.980 |
Why?
|
| Polymorphism, Genetic | 14 | 2014 | 4243 | 0.980 |
Why?
|
| Genetic Predisposition to Disease | 32 | 2022 | 17904 | 0.960 |
Why?
|
| Female | 215 | 2024 | 392644 | 0.950 |
Why?
|
| Middle Aged | 173 | 2024 | 220895 | 0.930 |
Why?
|
| Prospective Studies | 94 | 2024 | 54425 | 0.880 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2010 | 362 | 0.880 |
Why?
|
| Risk Assessment | 39 | 2024 | 23995 | 0.880 |
Why?
|
| Television | 2 | 2016 | 408 | 0.860 |
Why?
|
| Ischemic Attack, Transient | 5 | 2023 | 882 | 0.820 |
Why?
|
| Parkinson Disease | 7 | 2024 | 2877 | 0.820 |
Why?
|
| Cluster Headache | 8 | 2014 | 54 | 0.800 |
Why?
|
| Berlin | 11 | 2024 | 23 | 0.800 |
Why?
|
| Respiratory Insufficiency | 9 | 2022 | 1230 | 0.780 |
Why?
|
| Platelet Transfusion | 1 | 2024 | 297 | 0.760 |
Why?
|
| Aged | 130 | 2024 | 169289 | 0.740 |
Why?
|
| Male | 193 | 2024 | 360804 | 0.740 |
Why?
|
| Intensive Care Units | 8 | 2024 | 3745 | 0.720 |
Why?
|
| Population Surveillance | 4 | 2018 | 2598 | 0.720 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 3 | 2014 | 324 | 0.710 |
Why?
|
| Cognition Disorders | 9 | 2015 | 3979 | 0.710 |
Why?
|
| Vitamin E | 8 | 2012 | 872 | 0.710 |
Why?
|
| Prevalence | 33 | 2023 | 15732 | 0.700 |
Why?
|
| Randomized Controlled Trials as Topic | 32 | 2024 | 10209 | 0.690 |
Why?
|
| Schools | 6 | 2024 | 1489 | 0.690 |
Why?
|
| Positive-Pressure Respiration | 5 | 2018 | 639 | 0.680 |
Why?
|
| Thoracic Injuries | 1 | 2022 | 288 | 0.670 |
Why?
|
| Myocardial Infarction | 16 | 2024 | 11460 | 0.670 |
Why?
|
| Smoking | 19 | 2020 | 9053 | 0.670 |
Why?
|
| Polymorphism, Single Nucleotide | 22 | 2022 | 15936 | 0.650 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2021 | 1390 | 0.650 |
Why?
|
| Vascular System Injuries | 1 | 2022 | 246 | 0.630 |
Why?
|
| Recovery of Function | 5 | 2017 | 2979 | 0.620 |
Why?
|
| Comorbidity | 28 | 2019 | 10508 | 0.620 |
Why?
|
| Coronavirus | 1 | 2020 | 154 | 0.610 |
Why?
|
| Students | 5 | 2024 | 1741 | 0.610 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2021 | 1164 | 0.600 |
Why?
|
| Hyperlipidemias | 4 | 2020 | 771 | 0.600 |
Why?
|
| Causality | 8 | 2023 | 1242 | 0.600 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2019 | 110 | 0.600 |
Why?
|
| Body Mass Index | 23 | 2019 | 12953 | 0.590 |
Why?
|
| Cerebral Veins | 1 | 2019 | 157 | 0.590 |
Why?
|
| Risk | 25 | 2020 | 9610 | 0.590 |
Why?
|
| Analgesics | 5 | 2022 | 1070 | 0.580 |
Why?
|
| Authorship | 1 | 2020 | 284 | 0.570 |
Why?
|
| Cross-Sectional Studies | 26 | 2024 | 26125 | 0.570 |
Why?
|
| Genome-Wide Association Study | 17 | 2022 | 12690 | 0.570 |
Why?
|
| Tuna | 1 | 2016 | 18 | 0.560 |
Why?
|
| Aged, 80 and over | 60 | 2024 | 58976 | 0.550 |
Why?
|
| Dental Caries | 1 | 2020 | 428 | 0.540 |
Why?
|
| Cerebral Hemorrhage | 8 | 2023 | 2656 | 0.540 |
Why?
|
| Proportional Hazards Models | 31 | 2021 | 12463 | 0.540 |
Why?
|
| Obesity | 12 | 2020 | 12947 | 0.540 |
Why?
|
| Incidence | 35 | 2023 | 21353 | 0.530 |
Why?
|
| Alzheimer Disease | 5 | 2024 | 8599 | 0.520 |
Why?
|
| Medical Records | 3 | 2020 | 1408 | 0.520 |
Why?
|
| Seafood | 2 | 2016 | 393 | 0.510 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2022 | 807 | 0.510 |
Why?
|
| Myocardial Revascularization | 3 | 2016 | 790 | 0.510 |
Why?
|
| Dementia | 8 | 2024 | 2686 | 0.500 |
Why?
|
| Pain Measurement | 2 | 2020 | 3550 | 0.500 |
Why?
|
| Alcohol Drinking | 7 | 2016 | 4028 | 0.490 |
Why?
|
| Vascular Diseases | 3 | 2016 | 1161 | 0.490 |
Why?
|
| Cerebrovascular Disorders | 4 | 2019 | 1474 | 0.490 |
Why?
|
| Adult | 102 | 2024 | 221177 | 0.480 |
Why?
|
| Logistic Models | 26 | 2023 | 13255 | 0.480 |
Why?
|
| National Health Programs | 2 | 2017 | 440 | 0.480 |
Why?
|
| Coronary Disease | 6 | 2012 | 5914 | 0.470 |
Why?
|
| Health Status Indicators | 3 | 2017 | 970 | 0.470 |
Why?
|
| Kidney Diseases | 7 | 2011 | 2091 | 0.470 |
Why?
|
| Computers, Handheld | 1 | 2016 | 210 | 0.470 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3084 | 0.460 |
Why?
|
| Follow-Up Studies | 41 | 2021 | 39106 | 0.460 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3204 | 0.460 |
Why?
|
| Age Distribution | 10 | 2016 | 2880 | 0.460 |
Why?
|
| Hypertension | 13 | 2023 | 8540 | 0.440 |
Why?
|
| Tinnitus | 1 | 2016 | 196 | 0.440 |
Why?
|
| Bariatric Surgery | 1 | 2023 | 992 | 0.440 |
Why?
|
| Confidence Intervals | 13 | 2021 | 2927 | 0.440 |
Why?
|
| Blood Vessels | 2 | 2010 | 1113 | 0.430 |
Why?
|
| Computers | 1 | 2016 | 593 | 0.430 |
Why?
|
| Resuscitation | 1 | 2018 | 673 | 0.430 |
Why?
|
| Odds Ratio | 23 | 2016 | 9646 | 0.430 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 1654 | 0.430 |
Why?
|
| Lipids | 5 | 2020 | 3341 | 0.420 |
Why?
|
| Life Style | 8 | 2021 | 3917 | 0.420 |
Why?
|
| Pandemics | 9 | 2024 | 8654 | 0.410 |
Why?
|
| Case-Control Studies | 36 | 2022 | 22176 | 0.410 |
Why?
|
| Obesity, Morbid | 1 | 2023 | 1277 | 0.410 |
Why?
|
| Neuropsychological Tests | 8 | 2024 | 7045 | 0.410 |
Why?
|
| Hospital Mortality | 11 | 2018 | 5294 | 0.410 |
Why?
|
| Men's Health | 1 | 2012 | 73 | 0.410 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 1896 | 0.410 |
Why?
|
| Caregivers | 1 | 2024 | 2237 | 0.410 |
Why?
|
| Mortality | 3 | 2020 | 2901 | 0.400 |
Why?
|
| Statistics as Topic | 2 | 2016 | 2358 | 0.400 |
Why?
|
| Cardiology | 1 | 2023 | 1656 | 0.400 |
Why?
|
| Genetic Loci | 5 | 2022 | 2632 | 0.400 |
Why?
|
| Brain Diseases | 6 | 2018 | 1545 | 0.390 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2018 | 3708 | 0.390 |
Why?
|
| Lymphotoxin-alpha | 1 | 2011 | 93 | 0.380 |
Why?
|
| Educational Status | 5 | 2024 | 2522 | 0.380 |
Why?
|
| Leukoencephalopathies | 1 | 2014 | 256 | 0.380 |
Why?
|
| Coffee | 2 | 2018 | 593 | 0.370 |
Why?
|
| Age Factors | 24 | 2024 | 18395 | 0.370 |
Why?
|
| Health Services Research | 2 | 2020 | 1812 | 0.370 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 1462 | 0.370 |
Why?
|
| Fibromyalgia | 1 | 2015 | 405 | 0.360 |
Why?
|
| United States | 49 | 2024 | 72334 | 0.360 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2013 | 488 | 0.360 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2011 | 122 | 0.360 |
Why?
|
| Intraoperative Care | 4 | 2018 | 767 | 0.350 |
Why?
|
| Fibrinolytic Agents | 4 | 2009 | 2084 | 0.350 |
Why?
|
| Double-Blind Method | 17 | 2021 | 12341 | 0.350 |
Why?
|
| Biomedical Research | 3 | 2020 | 3429 | 0.350 |
Why?
|
| Self Concept | 1 | 2016 | 1045 | 0.340 |
Why?
|
| Food Supply | 1 | 2015 | 544 | 0.340 |
Why?
|
| Epilepsy | 4 | 2024 | 3290 | 0.340 |
Why?
|
| Cooking | 1 | 2012 | 315 | 0.330 |
Why?
|
| Public Health | 3 | 2018 | 2669 | 0.330 |
Why?
|
| Psychotic Disorders | 1 | 2024 | 3223 | 0.330 |
Why?
|
| Proton Pump Inhibitors | 1 | 2014 | 532 | 0.320 |
Why?
|
| Receptors, Neuropeptide | 4 | 2015 | 106 | 0.320 |
Why?
|
| Prostatic Neoplasms | 17 | 2023 | 11118 | 0.320 |
Why?
|
| Respiration Disorders | 3 | 2017 | 367 | 0.320 |
Why?
|
| Exercise | 4 | 2016 | 5890 | 0.320 |
Why?
|
| Quality of Life | 10 | 2024 | 13367 | 0.320 |
Why?
|
| Cerebral Infarction | 3 | 2011 | 983 | 0.310 |
Why?
|
| Motor Activity | 4 | 2011 | 2715 | 0.310 |
Why?
|
| Blood Pressure | 7 | 2023 | 8481 | 0.310 |
Why?
|
| Vitamins | 4 | 2012 | 1635 | 0.310 |
Why?
|
| Critical Illness | 4 | 2016 | 2723 | 0.310 |
Why?
|
| Sex Characteristics | 3 | 2020 | 2639 | 0.310 |
Why?
|
| Endovascular Procedures | 1 | 2022 | 2183 | 0.310 |
Why?
|
| Sex Distribution | 6 | 2016 | 2281 | 0.310 |
Why?
|
| Adiposity | 1 | 2018 | 1878 | 0.300 |
Why?
|
| Angiotensinogen | 1 | 2008 | 161 | 0.300 |
Why?
|
| Postoperative Complications | 12 | 2021 | 15631 | 0.300 |
Why?
|
| Adiponectin | 4 | 2015 | 1113 | 0.300 |
Why?
|
| Anesthesiology | 1 | 2018 | 1117 | 0.300 |
Why?
|
| Registries | 16 | 2022 | 8224 | 0.300 |
Why?
|
| Angina Pectoris | 1 | 2012 | 959 | 0.300 |
Why?
|
| Nuts | 1 | 2010 | 264 | 0.300 |
Why?
|
| Prognosis | 21 | 2021 | 29625 | 0.300 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 943 | 0.300 |
Why?
|
| Sex Factors | 16 | 2022 | 10552 | 0.290 |
Why?
|
| Databases as Topic | 1 | 2009 | 473 | 0.290 |
Why?
|
| Cholesterol | 8 | 2012 | 2904 | 0.290 |
Why?
|
| Feeding Behavior | 2 | 2010 | 3188 | 0.290 |
Why?
|
| Acetaminophen | 3 | 2006 | 554 | 0.290 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2020 | 190 | 0.290 |
Why?
|
| Brain Infarction | 1 | 2009 | 290 | 0.280 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2010 | 339 | 0.280 |
Why?
|
| Telomere | 1 | 2013 | 943 | 0.280 |
Why?
|
| Models, Theoretical | 2 | 2009 | 3575 | 0.280 |
Why?
|
| Vitamin D | 1 | 2021 | 3303 | 0.280 |
Why?
|
| Aging | 6 | 2011 | 8708 | 0.280 |
Why?
|
| Ascorbic Acid | 4 | 2012 | 655 | 0.270 |
Why?
|
| Suicide, Attempted | 1 | 2015 | 1402 | 0.270 |
Why?
|
| Social Class | 2 | 2024 | 2004 | 0.270 |
Why?
|
| Societies, Medical | 2 | 2018 | 3905 | 0.270 |
Why?
|
| Depression | 7 | 2022 | 8124 | 0.270 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2006 | 361 | 0.270 |
Why?
|
| Triglycerides | 5 | 2019 | 2461 | 0.260 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 656 | 0.260 |
Why?
|
| Length of Stay | 5 | 2018 | 6425 | 0.260 |
Why?
|
| Algorithms | 6 | 2022 | 14031 | 0.260 |
Why?
|
| Data Interpretation, Statistical | 4 | 2010 | 2691 | 0.260 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 582 | 0.260 |
Why?
|
| Mobile Health Units | 2 | 2023 | 92 | 0.260 |
Why?
|
| Intubation, Intratracheal | 6 | 2018 | 1329 | 0.260 |
Why?
|
| Receptors, Androgen | 2 | 2010 | 1079 | 0.260 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 299 | 0.260 |
Why?
|
| Leptin | 4 | 2015 | 1597 | 0.260 |
Why?
|
| beta Carotene | 8 | 2010 | 523 | 0.260 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2006 | 370 | 0.250 |
Why?
|
| Genotype | 16 | 2021 | 12990 | 0.250 |
Why?
|
| Diabetes Complications | 4 | 2020 | 1315 | 0.250 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 1129 | 0.250 |
Why?
|
| Suicidal Ideation | 1 | 2015 | 1447 | 0.250 |
Why?
|
| Thrombolytic Therapy | 3 | 2023 | 2064 | 0.250 |
Why?
|
| Physicians | 16 | 2012 | 4591 | 0.250 |
Why?
|
| Dyspepsia | 1 | 2006 | 116 | 0.240 |
Why?
|
| Neuromuscular Blocking Agents | 3 | 2016 | 129 | 0.240 |
Why?
|
| Stress, Psychological | 2 | 2024 | 4481 | 0.240 |
Why?
|
| Models, Statistical | 5 | 2021 | 5079 | 0.240 |
Why?
|
| Income | 2 | 2024 | 1877 | 0.240 |
Why?
|
| Diet, Mediterranean | 1 | 2012 | 740 | 0.240 |
Why?
|
| Italy | 3 | 2024 | 842 | 0.240 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2024 | 2199 | 0.240 |
Why?
|
| Antioxidants | 5 | 2011 | 1668 | 0.240 |
Why?
|
| Sequence Deletion | 1 | 2009 | 1494 | 0.240 |
Why?
|
| Neoplasms | 11 | 2012 | 22170 | 0.230 |
Why?
|
| Neurology | 1 | 2012 | 780 | 0.230 |
Why?
|
| Treatment Outcome | 25 | 2024 | 64680 | 0.230 |
Why?
|
| Cognition | 3 | 2023 | 6990 | 0.230 |
Why?
|
| Young Adult | 22 | 2024 | 59243 | 0.230 |
Why?
|
| Benzodiazepines | 3 | 2015 | 1132 | 0.230 |
Why?
|
| Adolescent | 27 | 2024 | 88319 | 0.230 |
Why?
|
| Renin-Angiotensin System | 1 | 2008 | 737 | 0.230 |
Why?
|
| Heart Arrest | 4 | 2021 | 1514 | 0.220 |
Why?
|
| Cerebral Arteries | 4 | 2010 | 490 | 0.220 |
Why?
|
| Therapeutics | 1 | 2004 | 113 | 0.220 |
Why?
|
| Common Cold | 1 | 2003 | 63 | 0.220 |
Why?
|
| Health Resources | 1 | 2009 | 935 | 0.220 |
Why?
|
| Severity of Illness Index | 7 | 2016 | 15842 | 0.220 |
Why?
|
| International Classification of Diseases | 1 | 2009 | 909 | 0.220 |
Why?
|
| Genetic Markers | 4 | 2016 | 2601 | 0.210 |
Why?
|
| Chickenpox | 1 | 2023 | 96 | 0.210 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2008 | 574 | 0.210 |
Why?
|
| Delirium | 1 | 2014 | 1668 | 0.210 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4811 | 0.210 |
Why?
|
| Research Design | 8 | 2022 | 6180 | 0.210 |
Why?
|
| Diet | 4 | 2014 | 8075 | 0.210 |
Why?
|
| Nonprescription Drugs | 1 | 2003 | 118 | 0.210 |
Why?
|
| Inpatients | 2 | 2021 | 2548 | 0.210 |
Why?
|
| Probability | 4 | 2023 | 2477 | 0.200 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 2 | 2016 | 42 | 0.200 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 1792 | 0.200 |
Why?
|
| Netherlands | 2 | 2024 | 2221 | 0.200 |
Why?
|
| Predictive Value of Tests | 11 | 2016 | 15266 | 0.200 |
Why?
|
| Weight Gain | 1 | 2012 | 2348 | 0.200 |
Why?
|
| Chronic Disease | 8 | 2020 | 9318 | 0.200 |
Why?
|
| Research Support as Topic | 1 | 2006 | 697 | 0.200 |
Why?
|
| Macular Degeneration | 2 | 2024 | 1007 | 0.200 |
Why?
|
| Hospitals | 3 | 2023 | 3882 | 0.190 |
Why?
|
| Erectile Dysfunction | 2 | 2023 | 444 | 0.190 |
Why?
|
| Editorial Policies | 1 | 2006 | 458 | 0.190 |
Why?
|
| Conflict of Interest | 1 | 2006 | 554 | 0.190 |
Why?
|
| Pneumonia | 4 | 2023 | 2143 | 0.190 |
Why?
|
| Gene Frequency | 5 | 2011 | 3606 | 0.190 |
Why?
|
| Cerebrovascular Circulation | 2 | 2011 | 2727 | 0.190 |
Why?
|
| Carcinoma | 1 | 2012 | 2330 | 0.190 |
Why?
|
| Dental Caries Susceptibility | 1 | 2020 | 26 | 0.180 |
Why?
|
| Critical Care | 4 | 2020 | 2696 | 0.180 |
Why?
|
| Telemedicine | 3 | 2024 | 3051 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 9 | 2011 | 2176 | 0.180 |
Why?
|
| Reproducibility of Results | 10 | 2020 | 20098 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 4352 | 0.180 |
Why?
|
| Urinary Incontinence | 2 | 2023 | 489 | 0.180 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2018 | 116 | 0.180 |
Why?
|
| Longitudinal Studies | 11 | 2022 | 14605 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2019 | 12148 | 0.180 |
Why?
|
| Multivariate Analysis | 12 | 2012 | 12059 | 0.180 |
Why?
|
| Intracranial Thrombosis | 1 | 2021 | 108 | 0.180 |
Why?
|
| Cholesterol, LDL | 4 | 2019 | 2382 | 0.180 |
Why?
|
| Self Efficacy | 1 | 2024 | 638 | 0.180 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 575 | 0.180 |
Why?
|
| Brain | 7 | 2016 | 27112 | 0.180 |
Why?
|
| Vasopressins | 1 | 2021 | 351 | 0.180 |
Why?
|
| Insecticides | 1 | 2021 | 191 | 0.170 |
Why?
|
| Myocardial Ischemia | 2 | 2008 | 2113 | 0.170 |
Why?
|
| Methylprednisolone | 1 | 2021 | 385 | 0.170 |
Why?
|
| Pulmonary Edema | 3 | 2018 | 409 | 0.170 |
Why?
|
| Physical Fitness | 2 | 2019 | 743 | 0.170 |
Why?
|
| Continuity of Patient Care | 3 | 2021 | 1069 | 0.170 |
Why?
|
| Cough | 1 | 2003 | 594 | 0.170 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2018 | 1875 | 0.170 |
Why?
|
| Wounds and Injuries | 2 | 2014 | 2491 | 0.170 |
Why?
|
| Neostigmine | 3 | 2015 | 68 | 0.160 |
Why?
|
| Video Recording | 1 | 2024 | 966 | 0.160 |
Why?
|
| C-Reactive Protein | 6 | 2012 | 3826 | 0.160 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2003 | 1033 | 0.160 |
Why?
|
| Renal Dialysis | 1 | 2008 | 1797 | 0.160 |
Why?
|
| Health Behavior | 3 | 2008 | 2643 | 0.160 |
Why?
|
| Regression Analysis | 4 | 2022 | 6343 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 5 | 2013 | 6075 | 0.160 |
Why?
|
| Health Status | 3 | 2010 | 4077 | 0.160 |
Why?
|
| Pneumococcal Infections | 1 | 2023 | 501 | 0.160 |
Why?
|
| Rehydration Solutions | 1 | 2018 | 43 | 0.150 |
Why?
|
| Hemostasis | 1 | 2021 | 467 | 0.150 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2021 | 307 | 0.150 |
Why?
|
| Defibrillators | 1 | 2018 | 39 | 0.150 |
Why?
|
| Cholesterol, HDL | 5 | 2019 | 1814 | 0.150 |
Why?
|
| Communicable Disease Control | 2 | 2021 | 846 | 0.150 |
Why?
|
| Cardiovascular Agents | 2 | 2021 | 840 | 0.150 |
Why?
|
| Child | 18 | 2024 | 80153 | 0.150 |
Why?
|
| Respiration, Artificial | 3 | 2018 | 2628 | 0.150 |
Why?
|
| Atherosclerosis | 2 | 2014 | 3408 | 0.150 |
Why?
|
| Patient Participation | 1 | 2007 | 1444 | 0.150 |
Why?
|
| Sumatriptan | 2 | 2016 | 66 | 0.150 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 133 | 0.150 |
Why?
|
| Dental Care | 1 | 2020 | 285 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 2 | 2021 | 1922 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2009 | 215 | 0.140 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2010 | 2518 | 0.140 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2018 | 1469 | 0.140 |
Why?
|
| Internet | 1 | 2009 | 3092 | 0.140 |
Why?
|
| Interdisciplinary Communication | 2 | 2017 | 931 | 0.140 |
Why?
|
| Perception | 2 | 2021 | 1197 | 0.140 |
Why?
|
| Comparative Effectiveness Research | 1 | 2022 | 709 | 0.140 |
Why?
|
| Epinephrine | 2 | 2021 | 792 | 0.140 |
Why?
|
| Waist-Hip Ratio | 2 | 2008 | 518 | 0.140 |
Why?
|
| Tea | 1 | 2018 | 288 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 4420 | 0.140 |
Why?
|
| Placebos | 4 | 2021 | 1667 | 0.140 |
Why?
|
| Foramen Ovale, Patent | 2 | 2010 | 208 | 0.140 |
Why?
|
| Survival Analysis | 8 | 2017 | 10090 | 0.140 |
Why?
|
| Early Ambulation | 1 | 2016 | 49 | 0.140 |
Why?
|
| Epidemiologic Methods | 3 | 2011 | 1336 | 0.130 |
Why?
|
| Progestins | 1 | 2018 | 301 | 0.130 |
Why?
|
| Anti-HIV Agents | 2 | 2024 | 4527 | 0.130 |
Why?
|
| Checklist | 1 | 2023 | 827 | 0.130 |
Why?
|
| Family Characteristics | 1 | 2021 | 1004 | 0.130 |
Why?
|
| Contraceptives, Oral | 2 | 2009 | 554 | 0.130 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 2947 | 0.130 |
Why?
|
| Aorta, Thoracic | 1 | 2022 | 1096 | 0.130 |
Why?
|
| Hyperoxia | 1 | 2018 | 258 | 0.130 |
Why?
|
| alpha-Tocopherol | 3 | 2011 | 126 | 0.130 |
Why?
|
| Hypercholesterolemia | 4 | 2015 | 1141 | 0.130 |
Why?
|
| Health Surveys | 6 | 2019 | 4061 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2008 | 2781 | 0.130 |
Why?
|
| Time Factors | 14 | 2020 | 39967 | 0.130 |
Why?
|
| Ketorolac | 1 | 2016 | 94 | 0.120 |
Why?
|
| Quadriceps Muscle | 1 | 2016 | 156 | 0.120 |
Why?
|
| Iran | 1 | 2018 | 737 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 1380 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2006 | 1463 | 0.120 |
Why?
|
| Oral Health | 1 | 2020 | 492 | 0.120 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2011 | 829 | 0.120 |
Why?
|
| Mass Screening | 2 | 2010 | 5428 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2010 | 2898 | 0.120 |
Why?
|
| Dietary Supplements | 5 | 2012 | 3415 | 0.120 |
Why?
|
| Self Report | 4 | 2019 | 3724 | 0.120 |
Why?
|
| Climate | 2 | 2023 | 147 | 0.120 |
Why?
|
| Tidal Volume | 4 | 2018 | 488 | 0.120 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 981 | 0.120 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2016 | 345 | 0.120 |
Why?
|
| Genetic Pleiotropy | 1 | 2015 | 181 | 0.120 |
Why?
|
| Myogenic Regulatory Factors | 2 | 2011 | 103 | 0.120 |
Why?
|
| Rare Diseases | 1 | 2020 | 622 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2018 | 579 | 0.120 |
Why?
|
| Glycoproteins | 3 | 2011 | 2203 | 0.120 |
Why?
|
| HIV Infections | 5 | 2024 | 17351 | 0.110 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2007 | 451 | 0.110 |
Why?
|
| Ultrasonography, Interventional | 1 | 2022 | 1496 | 0.110 |
Why?
|
| Caffeine | 1 | 2018 | 700 | 0.110 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2017 | 411 | 0.110 |
Why?
|
| Mandatory Programs | 1 | 2014 | 86 | 0.110 |
Why?
|
| Menarche | 1 | 2016 | 532 | 0.110 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2018 | 339 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 9031 | 0.110 |
Why?
|
| Disease Progression | 6 | 2015 | 13506 | 0.110 |
Why?
|
| Anesthesia, General | 2 | 2018 | 1174 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 487 | 0.110 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 4234 | 0.110 |
Why?
|
| Patient Readmission | 2 | 2018 | 3270 | 0.110 |
Why?
|
| Publishing | 1 | 2020 | 833 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2011 | 4575 | 0.110 |
Why?
|
| Phenotype | 6 | 2021 | 16591 | 0.110 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 2735 | 0.110 |
Why?
|
| Physical Therapy Modalities | 1 | 2016 | 532 | 0.100 |
Why?
|
| Atropine | 1 | 2013 | 244 | 0.100 |
Why?
|
| Airway Obstruction | 1 | 2018 | 661 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 36426 | 0.100 |
Why?
|
| Risk Reduction Behavior | 2 | 2011 | 1112 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2021 | 2161 | 0.100 |
Why?
|
| Hematoma, Subdural | 1 | 2013 | 127 | 0.100 |
Why?
|
| Postmenopause | 1 | 2021 | 2513 | 0.100 |
Why?
|
| Asthma | 2 | 2008 | 6234 | 0.100 |
Why?
|
| Malaria | 1 | 2021 | 1227 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 1303 | 0.100 |
Why?
|
| Craniotomy | 1 | 2016 | 741 | 0.100 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2012 | 143 | 0.100 |
Why?
|
| Anesthetics, Inhalation | 1 | 2017 | 574 | 0.100 |
Why?
|
| Sarcopenia | 1 | 2016 | 372 | 0.100 |
Why?
|
| Phosphoproteins | 2 | 2011 | 2448 | 0.100 |
Why?
|
| Estrogens | 1 | 2018 | 1522 | 0.100 |
Why?
|
| Bradycardia | 1 | 2013 | 299 | 0.090 |
Why?
|
| Frail Elderly | 1 | 2016 | 765 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2007 | 1250 | 0.090 |
Why?
|
| Consensus | 2 | 2018 | 3123 | 0.090 |
Why?
|
| Creatinine | 6 | 2008 | 1899 | 0.090 |
Why?
|
| Europe | 3 | 2018 | 3422 | 0.090 |
Why?
|
| Thrombectomy | 1 | 2016 | 705 | 0.090 |
Why?
|
| Patient Care Planning | 1 | 2016 | 908 | 0.090 |
Why?
|
| Massachusetts | 7 | 2021 | 8830 | 0.090 |
Why?
|
| Serotonin Receptor Agonists | 2 | 2009 | 151 | 0.090 |
Why?
|
| Disabled Persons | 1 | 2020 | 1225 | 0.090 |
Why?
|
| Universities | 1 | 2016 | 993 | 0.090 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2014 | 702 | 0.090 |
Why?
|
| Patient Discharge | 3 | 2023 | 3443 | 0.090 |
Why?
|
| Hypolipidemic Agents | 1 | 2015 | 609 | 0.090 |
Why?
|
| Diet Surveys | 1 | 2014 | 1162 | 0.090 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 1087 | 0.090 |
Why?
|
| Racemases and Epimerases | 1 | 2011 | 114 | 0.090 |
Why?
|
| Oxygen | 3 | 2018 | 4227 | 0.090 |
Why?
|
| Hospitalization | 6 | 2023 | 10723 | 0.090 |
Why?
|
| Receptors, FSH | 1 | 2010 | 29 | 0.090 |
Why?
|
| Survivors | 1 | 2021 | 2371 | 0.090 |
Why?
|
| Retrospective Studies | 15 | 2022 | 80636 | 0.090 |
Why?
|
| Chemoprevention | 1 | 2012 | 326 | 0.090 |
Why?
|
| Abdomen | 1 | 2016 | 1128 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2011 | 313 | 0.090 |
Why?
|
| Chromosomes, Human, X | 1 | 2012 | 321 | 0.090 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 6935 | 0.090 |
Why?
|
| Psychological Tests | 1 | 2012 | 640 | 0.090 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 888 | 0.090 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2018 | 992 | 0.090 |
Why?
|
| Overweight | 3 | 2012 | 2417 | 0.090 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2010 | 86 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2011 | 430 | 0.080 |
Why?
|
| Aromatase | 1 | 2010 | 147 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 1666 | 0.080 |
Why?
|
| Inflammation | 1 | 2009 | 10773 | 0.080 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2011 | 311 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2024 | 14666 | 0.080 |
Why?
|
| Organ Size | 1 | 2014 | 2254 | 0.080 |
Why?
|
| Validation Studies as Topic | 1 | 2009 | 162 | 0.080 |
Why?
|
| Trichomonas Infections | 1 | 2009 | 41 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 6484 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 2421 | 0.080 |
Why?
|
| Estrogen Receptor beta | 1 | 2010 | 168 | 0.080 |
Why?
|
| Fishes | 1 | 2012 | 603 | 0.080 |
Why?
|
| Women | 1 | 2011 | 223 | 0.080 |
Why?
|
| Trichomonas vaginalis | 1 | 2009 | 70 | 0.080 |
Why?
|
| Patient Selection | 5 | 2016 | 4244 | 0.080 |
Why?
|
| Muscle Cells | 1 | 2010 | 195 | 0.080 |
Why?
|
| Joints | 1 | 2010 | 322 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2004 | 3763 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 638 | 0.080 |
Why?
|
| Alleles | 3 | 2022 | 6863 | 0.080 |
Why?
|
| Hyperacusis | 1 | 2009 | 31 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 21012 | 0.080 |
Why?
|
| Electroencephalography | 1 | 2024 | 6225 | 0.080 |
Why?
|
| Myoblasts | 1 | 2010 | 231 | 0.080 |
Why?
|
| Norway | 1 | 2010 | 499 | 0.080 |
Why?
|
| Anxiety | 2 | 2022 | 4573 | 0.080 |
Why?
|
| Forecasting | 1 | 2017 | 2928 | 0.080 |
Why?
|
| Endoribonucleases | 1 | 2010 | 228 | 0.080 |
Why?
|
| Cause of Death | 3 | 2015 | 3683 | 0.080 |
Why?
|
| Selenoproteins | 1 | 2010 | 215 | 0.080 |
Why?
|
| Photophobia | 1 | 2009 | 75 | 0.080 |
Why?
|
| Mesenchymal Stem Cells | 2 | 2010 | 1642 | 0.080 |
Why?
|
| Antibodies, Protozoan | 1 | 2009 | 252 | 0.080 |
Why?
|
| Muscle Development | 1 | 2010 | 259 | 0.080 |
Why?
|
| C-Peptide | 1 | 2010 | 440 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2018 | 2093 | 0.070 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2010 | 236 | 0.070 |
Why?
|
| Cystatins | 1 | 2007 | 55 | 0.070 |
Why?
|
| Kidney | 1 | 2003 | 7048 | 0.070 |
Why?
|
| Pain, Postoperative | 1 | 2018 | 1739 | 0.070 |
Why?
|
| Abdominal Fat | 1 | 2009 | 221 | 0.070 |
Why?
|
| Platinum Compounds | 1 | 2008 | 95 | 0.070 |
Why?
|
| Oleic Acid | 1 | 2008 | 92 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2009 | 418 | 0.070 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 492 | 0.070 |
Why?
|
| Dermatomycoses | 1 | 2007 | 48 | 0.070 |
Why?
|
| Adipokines | 1 | 2009 | 310 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 452 | 0.070 |
Why?
|
| Health Care Costs | 2 | 2011 | 3242 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2024 | 2571 | 0.070 |
Why?
|
| Watchful Waiting | 1 | 2011 | 491 | 0.070 |
Why?
|
| Onychomycosis | 1 | 2007 | 50 | 0.070 |
Why?
|
| Selenium | 1 | 2010 | 417 | 0.070 |
Why?
|
| Matched-Pair Analysis | 1 | 2007 | 284 | 0.070 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2011 | 620 | 0.070 |
Why?
|
| Chicago | 1 | 2007 | 254 | 0.070 |
Why?
|
| Insurance, Physician Services | 1 | 2006 | 23 | 0.070 |
Why?
|
| Anesthesia | 1 | 2018 | 1594 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 1379 | 0.070 |
Why?
|
| CADASIL | 1 | 2007 | 88 | 0.070 |
Why?
|
| Linoleic Acid | 1 | 2008 | 158 | 0.070 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2007 | 94 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2023 | 4686 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2010 | 960 | 0.070 |
Why?
|
| Epidemiologic Studies | 2 | 2007 | 675 | 0.070 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2006 | 56 | 0.070 |
Why?
|
| Glucose | 1 | 2018 | 4346 | 0.070 |
Why?
|
| DNA Mutational Analysis | 3 | 2009 | 4111 | 0.070 |
Why?
|
| Insurance Claim Reporting | 1 | 2006 | 166 | 0.060 |
Why?
|
| Blood Circulation | 2 | 2017 | 248 | 0.060 |
Why?
|
| Nausea | 1 | 2009 | 679 | 0.060 |
Why?
|
| Observation | 1 | 2007 | 310 | 0.060 |
Why?
|
| Pregnancy Trimester, First | 1 | 2010 | 907 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2006 | 318 | 0.060 |
Why?
|
| Pain | 1 | 2021 | 5073 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 4853 | 0.060 |
Why?
|
| Vomiting | 1 | 2009 | 651 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 3 | 2023 | 5492 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2007 | 678 | 0.060 |
Why?
|
| Mental Disorders | 2 | 2018 | 6845 | 0.060 |
Why?
|
| Insurance Claim Review | 1 | 2009 | 741 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2010 | 1934 | 0.060 |
Why?
|
| Risk Adjustment | 1 | 2009 | 600 | 0.060 |
Why?
|
| Diabetes Mellitus | 5 | 2013 | 5840 | 0.060 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2021 | 1007 | 0.060 |
Why?
|
| Placebo Effect | 1 | 2009 | 518 | 0.060 |
Why?
|
| Genetic Testing | 2 | 2009 | 3537 | 0.060 |
Why?
|
| Alanine | 1 | 2007 | 609 | 0.060 |
Why?
|
| Child, Preschool | 9 | 2022 | 42230 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2009 | 1186 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2016 | 2078 | 0.060 |
Why?
|
| Insurance, Health | 2 | 2014 | 2498 | 0.060 |
Why?
|
| Health Services | 1 | 2009 | 752 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 7827 | 0.060 |
Why?
|
| Cataract | 1 | 2010 | 832 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2007 | 352 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2010 | 787 | 0.060 |
Why?
|
| Analgesics, Opioid | 2 | 2018 | 3808 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2013 | 2751 | 0.060 |
Why?
|
| Mental Health | 1 | 2018 | 3250 | 0.060 |
Why?
|
| Disability Evaluation | 3 | 2016 | 1835 | 0.060 |
Why?
|
| Hospitalists | 1 | 2008 | 294 | 0.060 |
Why?
|
| Glycine | 1 | 2007 | 663 | 0.060 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2007 | 540 | 0.060 |
Why?
|
| Synovial Membrane | 1 | 2007 | 532 | 0.060 |
Why?
|
| Drainage | 1 | 2010 | 1157 | 0.060 |
Why?
|
| Pharmacoepidemiology | 1 | 2007 | 350 | 0.060 |
Why?
|
| Electric Countershock | 2 | 2018 | 533 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 597 | 0.060 |
Why?
|
| Tropical Climate | 1 | 2023 | 35 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2007 | 633 | 0.060 |
Why?
|
| Poverty | 1 | 2015 | 2698 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2010 | 2696 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 1886 | 0.060 |
Why?
|
| Penile Erection | 1 | 2023 | 100 | 0.060 |
Why?
|
| China | 1 | 2010 | 2369 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2011 | 1186 | 0.060 |
Why?
|
| Triazoles | 1 | 2009 | 903 | 0.050 |
Why?
|
| Internationality | 1 | 2009 | 1001 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2009 | 1475 | 0.050 |
Why?
|
| Ambulances | 1 | 2023 | 91 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 10766 | 0.050 |
Why?
|
| Gene Expression | 1 | 2016 | 7581 | 0.050 |
Why?
|
| Neoplasm Staging | 4 | 2011 | 11121 | 0.050 |
Why?
|
| Osteoarthritis | 1 | 2010 | 1063 | 0.050 |
Why?
|
| Walking | 1 | 2010 | 1198 | 0.050 |
Why?
|
| Colombia | 1 | 2023 | 282 | 0.050 |
Why?
|
| Viral Load | 2 | 2023 | 3332 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2010 | 3208 | 0.050 |
Why?
|
| Adipocytes | 1 | 2009 | 1194 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2023 | 159 | 0.050 |
Why?
|
| Humidity | 1 | 2023 | 205 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2010 | 1374 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2007 | 752 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2009 | 2426 | 0.050 |
Why?
|
| Survival Rate | 4 | 2012 | 12725 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2009 | 6228 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 2416 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2006 | 1416 | 0.050 |
Why?
|
| Preventive Health Services | 1 | 2006 | 567 | 0.050 |
Why?
|
| Mexico | 2 | 2014 | 764 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2023 | 328 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2011 | 1936 | 0.050 |
Why?
|
| Fibrinopeptide A | 1 | 2021 | 43 | 0.050 |
Why?
|
| Quinazolines | 1 | 2008 | 1371 | 0.050 |
Why?
|
| Drug Costs | 1 | 2009 | 1183 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2011 | 3442 | 0.050 |
Why?
|
| Hospital Costs | 2 | 2018 | 947 | 0.050 |
Why?
|
| Infant | 7 | 2023 | 36192 | 0.050 |
Why?
|
| Factor XI | 1 | 2021 | 34 | 0.050 |
Why?
|
| Prothrombin Time | 1 | 2021 | 117 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2018 | 4761 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2010 | 2571 | 0.050 |
Why?
|
| Factor VII | 1 | 2021 | 139 | 0.050 |
Why?
|
| Linear Models | 2 | 2010 | 5871 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2009 | 7856 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 4876 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2011 | 1909 | 0.040 |
Why?
|
| Polysomnography | 2 | 2018 | 1848 | 0.040 |
Why?
|
| Partial Thromboplastin Time | 1 | 2021 | 204 | 0.040 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2020 | 69 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 1208 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2003 | 992 | 0.040 |
Why?
|
| Integrin beta Chains | 1 | 2020 | 115 | 0.040 |
Why?
|
| Longevity | 1 | 2008 | 1065 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2021 | 277 | 0.040 |
Why?
|
| Sample Size | 1 | 2023 | 841 | 0.040 |
Why?
|
| Prostatectomy | 2 | 2023 | 1824 | 0.040 |
Why?
|
| Quantitative Trait Loci | 2 | 2022 | 2116 | 0.040 |
Why?
|
| Cartilage, Articular | 1 | 2007 | 1099 | 0.040 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 1273 | 0.040 |
Why?
|
| Electronics | 1 | 2021 | 318 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2016 | 1440 | 0.040 |
Why?
|
| Homeostasis | 1 | 2010 | 3323 | 0.040 |
Why?
|
| Pneumococcal Vaccines | 1 | 2023 | 397 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2022 | 522 | 0.040 |
Why?
|
| Emergency Medical Services | 2 | 2023 | 1923 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 1702 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 809 | 0.040 |
Why?
|
| Denmark | 1 | 2021 | 771 | 0.040 |
Why?
|
| Hypersensitivity | 1 | 2008 | 1171 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2021 | 382 | 0.040 |
Why?
|
| Desogestrel | 1 | 2018 | 17 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2021 | 279 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 422 | 0.040 |
Why?
|
| Reference Values | 3 | 2013 | 4920 | 0.040 |
Why?
|
| Hematoma | 1 | 2023 | 768 | 0.040 |
Why?
|
| Factor VIII | 1 | 2021 | 348 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 176 | 0.040 |
Why?
|
| Recurrence | 4 | 2020 | 8465 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2021 | 916 | 0.040 |
Why?
|
| Quarantine | 1 | 2020 | 181 | 0.040 |
Why?
|
| Superior Sagittal Sinus | 1 | 2017 | 15 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 2471 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2007 | 2025 | 0.040 |
Why?
|
| Animals | 8 | 2016 | 168459 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 654 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2010 | 2053 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 6403 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2023 | 730 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2009 | 3312 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2021 | 888 | 0.040 |
Why?
|
| Peptides | 1 | 2009 | 4358 | 0.040 |
Why?
|
| Seasons | 1 | 2023 | 1520 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2010 | 416 | 0.040 |
Why?
|
| Microarray Analysis | 2 | 2011 | 749 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 673 | 0.040 |
Why?
|
| Exhalation | 1 | 2018 | 181 | 0.030 |
Why?
|
| Cortical Spreading Depression | 2 | 2011 | 288 | 0.030 |
Why?
|
| Social Support | 1 | 2006 | 2171 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2021 | 881 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2010 | 4936 | 0.030 |
Why?
|
| Uncertainty | 1 | 2021 | 754 | 0.030 |
Why?
|
| Nurses | 2 | 2017 | 2478 | 0.030 |
Why?
|
| Public Opinion | 1 | 2020 | 484 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2018 | 250 | 0.030 |
Why?
|
| Sweden | 1 | 2019 | 1379 | 0.030 |
Why?
|
| Outpatients | 1 | 2024 | 1597 | 0.030 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2019 | 323 | 0.030 |
Why?
|
| Austria | 1 | 2016 | 207 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2017 | 510 | 0.030 |
Why?
|
| Emergencies | 1 | 2022 | 1217 | 0.030 |
Why?
|
| Boston | 1 | 2009 | 9326 | 0.030 |
Why?
|
| Software | 1 | 2009 | 4434 | 0.030 |
Why?
|
| Workplace | 1 | 2022 | 863 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 5796 | 0.030 |
Why?
|
| Insulin | 1 | 2010 | 6596 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2012 | 2048 | 0.030 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2018 | 543 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2330 | 0.030 |
Why?
|
| Telomerase | 1 | 2020 | 745 | 0.030 |
Why?
|
| Mutation | 2 | 2011 | 30052 | 0.030 |
Why?
|
| Contraception | 1 | 2018 | 349 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 551 | 0.030 |
Why?
|
| India | 1 | 2021 | 2348 | 0.030 |
Why?
|
| Quebec | 1 | 2014 | 141 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2015 | 160 | 0.030 |
Why?
|
| Atlases as Topic | 1 | 2016 | 248 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2022 | 1336 | 0.030 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2015 | 177 | 0.030 |
Why?
|
| Spirometry | 1 | 2018 | 929 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2022 | 834 | 0.030 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1998 | 748 | 0.030 |
Why?
|
| Haplotypes | 2 | 2012 | 2713 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2024 | 1784 | 0.030 |
Why?
|
| Arteriosclerosis | 1 | 1998 | 1055 | 0.030 |
Why?
|
| Acute Disease | 2 | 2020 | 7237 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 1089 | 0.030 |
Why?
|
| Social Behavior | 1 | 2020 | 1135 | 0.030 |
Why?
|
| Aphasia | 1 | 2015 | 192 | 0.030 |
Why?
|
| Models, Biological | 1 | 2010 | 9469 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2024 | 2775 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 1349 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2021 | 1376 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2011 | 5127 | 0.030 |
Why?
|
| Melanesia | 1 | 2012 | 13 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 437 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 1572 | 0.030 |
Why?
|
| Health Services for the Aged | 1 | 2015 | 259 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2015 | 897 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2008 | 4792 | 0.030 |
Why?
|
| Thrombosis | 1 | 2006 | 2942 | 0.030 |
Why?
|
| Anesthetics | 1 | 2018 | 523 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 1749 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 926 | 0.030 |
Why?
|
| Reference Standards | 1 | 2016 | 1003 | 0.020 |
Why?
|
| Infant, Newborn | 4 | 2016 | 26198 | 0.020 |
Why?
|
| Calcium Channels, N-Type | 1 | 2011 | 43 | 0.020 |
Why?
|
| Genes, X-Linked | 1 | 2012 | 128 | 0.020 |
Why?
|
| Pain Threshold | 1 | 2016 | 604 | 0.020 |
Why?
|
| International Cooperation | 1 | 2018 | 1422 | 0.020 |
Why?
|
| Hyperalgesia | 1 | 2016 | 531 | 0.020 |
Why?
|
| Visual Acuity | 2 | 2012 | 2672 | 0.020 |
Why?
|
| Seizures | 1 | 2024 | 2957 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2015 | 1638 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 6346 | 0.020 |
Why?
|
| Health Personnel | 1 | 2005 | 3335 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 9420 | 0.020 |
Why?
|
| Retreatment | 1 | 2012 | 598 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2021 | 5247 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2024 | 6240 | 0.020 |
Why?
|
| Wakefulness | 1 | 2018 | 1265 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2014 | 1045 | 0.020 |
Why?
|
| Premenopause | 1 | 2014 | 1039 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 675 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 3156 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2010 | 862 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 5315 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2009 | 23445 | 0.020 |
Why?
|
| Interleukin-9 | 1 | 2009 | 62 | 0.020 |
Why?
|
| Population Groups | 1 | 2010 | 208 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 5440 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2016 | 1410 | 0.020 |
Why?
|
| Nursing Homes | 1 | 2016 | 1082 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 1165 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2013 | 617 | 0.020 |
Why?
|
| Melanoma | 1 | 2007 | 5709 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 6019 | 0.020 |
Why?
|
| Musculoskeletal System | 1 | 2010 | 188 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 506 | 0.020 |
Why?
|
| Receptors, CCR2 | 1 | 2009 | 215 | 0.020 |
Why?
|
| Genetic Variation | 2 | 2018 | 6567 | 0.020 |
Why?
|
| Pregnancy | 1 | 2010 | 29874 | 0.020 |
Why?
|
| British Columbia | 1 | 2008 | 241 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2008 | 5880 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 8529 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2007 | 37 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 613 | 0.020 |
Why?
|
| Collagen Type X | 1 | 2007 | 16 | 0.020 |
Why?
|
| Collagen Type XI | 1 | 2007 | 21 | 0.020 |
Why?
|
| Collagen Type IX | 1 | 2007 | 20 | 0.020 |
Why?
|
| Observer Variation | 2 | 2005 | 2606 | 0.020 |
Why?
|
| Itraconazole | 1 | 2007 | 43 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT1D | 1 | 2007 | 9 | 0.020 |
Why?
|
| ROC Curve | 1 | 2015 | 3579 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 208 | 0.020 |
Why?
|
| Control Groups | 1 | 2007 | 104 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2007 | 36 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 1126 | 0.020 |
Why?
|
| Aggrecans | 1 | 2007 | 89 | 0.020 |
Why?
|
| Regenerative Medicine | 1 | 2010 | 306 | 0.020 |
Why?
|
| Stem Cells | 2 | 2010 | 3522 | 0.020 |
Why?
|
| Fluconazole | 1 | 2007 | 157 | 0.020 |
Why?
|
| Cartilage | 1 | 2010 | 806 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2007 | 148 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 3245 | 0.020 |
Why?
|
| Transaminases | 1 | 2007 | 198 | 0.020 |
Why?
|
| High Mobility Group Proteins | 1 | 2007 | 177 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2013 | 1420 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 629 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2007 | 198 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 1403 | 0.020 |
Why?
|
| Endothelium | 1 | 2009 | 765 | 0.020 |
Why?
|
| SOX9 Transcription Factor | 1 | 2007 | 145 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2011 | 697 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2008 | 557 | 0.020 |
Why?
|
| Cataract Extraction | 1 | 2010 | 467 | 0.020 |
Why?
|
| Cystatin C | 1 | 2007 | 269 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2009 | 705 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2009 | 598 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 1217 | 0.020 |
Why?
|
| Serine | 1 | 2010 | 830 | 0.020 |
Why?
|
| Cerebellum | 1 | 2013 | 1501 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2007 | 523 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 1924 | 0.020 |
Why?
|
| Self Medication | 1 | 2006 | 117 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2009 | 629 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2008 | 629 | 0.020 |
Why?
|
| Proteins | 1 | 2020 | 6032 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2010 | 1998 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2014 | 1247 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 13639 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2014 | 1081 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 9177 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 1787 | 0.010 |
Why?
|
| Alcoholic Beverages | 1 | 2006 | 264 | 0.010 |
Why?
|
| Pedigree | 1 | 2012 | 4542 | 0.010 |
Why?
|
| Selection Bias | 1 | 2006 | 359 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2008 | 857 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2007 | 616 | 0.010 |
Why?
|
| Fasting | 1 | 2010 | 1603 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 13380 | 0.010 |
Why?
|
| Heart Failure | 1 | 2007 | 11669 | 0.010 |
Why?
|
| Diabetic Angiopathies | 1 | 2008 | 803 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 2014 | 2720 | 0.010 |
Why?
|
| Edetic Acid | 1 | 2003 | 280 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2008 | 1115 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 3810 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3778 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2007 | 795 | 0.010 |
Why?
|
| Sleep | 1 | 2018 | 4768 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2014 | 3728 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1648 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 2469 | 0.010 |
Why?
|
| Cattle | 1 | 2007 | 3849 | 0.010 |
Why?
|
| Telephone | 1 | 2005 | 627 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 3416 | 0.010 |
Why?
|
| Computational Biology | 1 | 2013 | 3518 | 0.010 |
Why?
|
| Base Sequence | 1 | 2012 | 12441 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 3595 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 4915 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 2015 | 3220 | 0.010 |
Why?
|
| Psychometrics | 1 | 2010 | 3065 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 1516 | 0.010 |
Why?
|
| Genomics | 1 | 2016 | 5821 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 12974 | 0.010 |
Why?
|
| Heterozygote | 1 | 2007 | 2787 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 4021 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2011 | 2056 | 0.010 |
Why?
|
| Lung | 1 | 2018 | 10000 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2003 | 676 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 2865 | 0.010 |
Why?
|
| Prostate | 1 | 2007 | 1770 | 0.010 |
Why?
|
| Transcription Factors | 2 | 2010 | 12128 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2011 | 2366 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8320 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 2244 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 1897 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 2759 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 6310 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 4948 | 0.010 |
Why?
|
| Biopsy | 1 | 2009 | 6766 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 2529 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 2169 | 0.010 |
Why?
|
| Body Weight | 1 | 2007 | 4618 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 3612 | 0.010 |
Why?
|
| Weight Loss | 1 | 2007 | 2684 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15601 | 0.010 |
Why?
|
| Language | 1 | 2005 | 1540 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 11076 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5305 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2003 | 1902 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 8631 | 0.010 |
Why?
|
| Mice | 2 | 2011 | 81525 | 0.010 |
Why?
|
| Endarterectomy, Carotid | 1 | 1999 | 555 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 4174 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2010 | 11528 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 9280 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 8002 | 0.010 |
Why?
|
| Apoptosis | 1 | 2009 | 9486 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 12795 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 22169 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1999 | 4812 | 0.000 |
Why?
|